Afatinib
From Proteopedia
(Difference between revisions)
| Line 8: | Line 8: | ||
<scene name='10/1014269/Cv/4'>Afatinib binding site</scene>. | <scene name='10/1014269/Cv/4'>Afatinib binding site</scene>. | ||
| - | <scene name='10/1014269/Cv/5'>Afatinib covalently binds to cysteine number 797</scene> of the epidermal growth factor receptor | + | <scene name='10/1014269/Cv/5'>Afatinib covalently binds to cysteine number 797</scene> of the epidermal growth factor receptor via a Michael addition (IC<sub>50</sub> = 0.5 nM).<ref name="a13">Schubert-Zsilavecz, M, Wurglics, M, Neue Arzneimittel Frühjahr 2013. (in German)</ref> |
</StructureSection> | </StructureSection> | ||
== References == | == References == | ||
<references/> | <references/> | ||
Revision as of 13:42, 14 December 2023
| |||||||||||
References
- ↑ Spreitzer H (13 May 2008). "Neue Wirkstoffe – Tovok". Österreichische Apothekerzeitung (in German) (10/2008): 498.
- ↑ 2.0 2.1 Minkovsky N, Berezov A. BIBW-2992, a dual receptor tyrosine kinase inhibitor for the treatment of solid tumors. Curr Opin Investig Drugs. 2008 Dec;9(12):1336-46 PMID:19037840
- ↑ "Gilotrif (afatinib)" (PDF). US Food and Drug Administration. Retrieved 11 March 2021.
- ↑ "Giotrif Afatinib (as afatinib dimaleate)" (PDF). TGA eBusiness Services. Boehringer Ingelheim Pty Limited. 7 November 2013. Retrieved 28 January 2014.
- ↑ Li D, Ambrogio L, Shimamura T, Kubo S, Takahashi M, Chirieac LR, Padera RF, Shapiro GI, Baum A, Himmelsbach F, Rettig WJ, Meyerson M, Solca F, Greulich H, Wong KK. BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models. Oncogene. 2008 Aug 7;27(34):4702-11. PMID:18408761 doi:10.1038/onc.2008.109
- ↑ Schubert-Zsilavecz, M, Wurglics, M, Neue Arzneimittel Frühjahr 2013. (in German)
